Kornimate/medical-research-clean huggingface dataset:
evaluation of the achievement of a pharmacodynamic target of piperacillin-tazobactam for the population with obesity

Conditions: Infections; Obesity and Obesity-related Medical Conditions

Summary: this study aims to evaluate the feasibility of an open randomized controlled study which would assess the proportion patients with obesity who will have a favorable pharmacodynamic parameter (i.e. ft\> 100% mic) after 24 hours of piperacillin-tazobactam administered as a prolonged intermittent infusion compared to a standard infusion.


Eligibility criteria:
inclusion criteria: * adults (18 years and older) * patients hospitalized at hôpital charles-le moyne * obesity (as defined by a body mass index of ≥ 30 kg/m\^2) * piperacillin-tazobactam prescription initiated within last 24 hours * planned duration of piperacillin-tazobactam of 24 hours or more exclusion criteria: * documented allergy to beta-lactams of the penicillin class * patients with renal replacement therapy (hemodialysis, peritoneal dialysis, continuous venovenous hemodiafiltration) * pregnancy * history of seizures or epilepsy, active seizures or epilepsy treated with antiepileptic drug therapy * patients on prolonged intermittent infusion or continuous infusion of piperacillin-tazobactam before randomization

Keywords: obesity piperacillin-tazobactam pharmacodynamics
composite probiotics stabilize lipid metabolism in chronic hepatitis b patients:a clinical trial

Conditions: Chronic Hepatitis B

Summary: the goal of this is to verify the clinical efficacy of compound probiotics in reducing hbv infection levels and regulating intestinal flora in patients with chronic hepatitis b. the main question it aims to answer is: • conventional antiviral therapy combined with a 3-month probiotic intervention was used to evaluate the clinical efficacy of reducing hbv infection levels (hbeag, hbsag, and hbv dna levels) and regulating gut microbiota.


Eligibility criteria:
inclusion criteria: 1. meet the hepatitis b clinical diagnostic criteria of the chronic hepatitis b prevention and treatment guidelines (2022 edition), excluding patients infected with hepatitis c virus, hepatitis d virus and other hepatitis viruses; 2. be aware of the content and purpose of this study, and voluntarily sign the treatment study consent. exclusion criteria: 1. patients infected within 3 months; 2. received antibiotic treatment within 3 months; 3. received probiotic and probiotic therapy within 3 months; 4. complicated with hypertension or diabetes; 5. obesity or significantly low weight; 6. obvious atherosclerosis; 7. chronic kidney disease; 8. inflammatory bowel disease, irritable bowel syndrome, or a history of gastrointestinal surgery; 9. malignant tumors; 10. autoimmune diseases; 11. mental illnesses such as parkinson's disease, alzheimer's disease and stroke; 12. pregnant or lactating women; 13. patients with cirrhosis or decompensated liver disease; 14. subjects cannot participate in the experiment due to their reasons; those who meet any of the above criteria will not be selected.
the effect of cognitive behavioral therapy on post-traumatic stress symptoms in nursing students

Conditions: Trauma and Stressor Related Disorders

Summary: objectives: this research was planned to examine the effect of cognitive behavioral therapy on the post-traumatic stress symptoms of nursing students during the covid-19 pandemic. design: single-blinded study with parallel groups. setting: faculty of nursing. participants: 60 first-year students studying at the faculty of nursing were randomly assigned to the intervention (n=30) and control (n=30) groups. method: data were collected using the information form prepared by the researcher and the post traumatic stress disorder checklist for dsm-5. the intervention group was collected online three times, before the cognitive behavioral group therapy, at the end of the therapy and three months later. group intervention program based on cognitive behavioral approach of ten sessions; face-to-face, the intervention group was divided into two separate groups and each group was completed in approximately one and a half months (may-june 2022), two days a week. follow-up measurement was completed in september 2022. while group therapy was applied to the intervention group, no intervention was made to the control group.


Eligibility criteria:
inclusion criteria: * being a first year nursing student exclusion criteria: * being a foreign student * having a psychiatric diagnosis

Keywords: nurse therapy post-traumatic stress
comparison of prognosis in endometrial cancer treated with different surgical methods: laparoscopy, robotic-assisted laparoscopy and laparotomy

Conditions: Endometrial Cancer

Summary: objective：to compare the clinical outcomes of endometrial cancer patients who received surgerical treatments: comparisons of robotic-assisted laparoscopic, laparoscopic and laparotomic methods

we will review the medical records of clinically uterine-confined endometrial cancer women who received robotic-assisted laparoscopic, laparoscopic or laparotomic methods; and compare their outcomes.

Eligibility criteria:
inclusion criteria: * womwn who received endometrial cancer surgical from january 01, 2008 to november 30, 2022 were be reviewed. exclusion criteria: * endometrial cancer patients did not undergo surgery.
talk therapy after stroke

Conditions: Adams-Stokes Syndrome

Summary: strokes are the first cause of acquired physical disability among adults. some studies proved that depression is often an unrecognized complication from stroke, associated with a vital prognosis, functional and cognitive pejorative diagnosis. it led us to pose the hypothesis of the existence of a particular psychological state after stroke particularly favorable to a psychotherapeutic alliance. so, this longitudinal monocentric study aims to estimate the feasibility of a talk therapy and its impact on the anxio-depressive symptomatology after stroke.


Eligibility criteria:
inclusion criteria: * ischemic or aemoragic stroke minor 1 week, confirmed by cerebral imaging exclusion criteria: * severe aphasia (nihss criteria 9: sup or egal: 2) * chronic psychiatric preexistant desease.
a study to compare bempegaldesleukin (bempeg: nktr-214) combined with nivolumab and tyrosine kinase inhibitor (tki) to nivolumab and tki alone in participants with previously untreated kidney cancer that is advanced or has spread

Conditions: Renal Cell Carcinoma

Summary: the purpose of this study is in part 1, to determine the safety of nivolumab, bempegaldesleukin (bempeg: nktr-214), and tyrosine kinase inhibitor (tki) combination.


Eligibility criteria:
inclusion criteria: * histological confirmation of renal cell carcinoma (rcc) with clear cell component including participants who may also have sarcomatoid features * advanced (not amenable to curative surgery or radiation therapy) or metastatic (american joint committee on cancer (ajcc) stage 4) rcc * no prior systemic therapy, including prior pd-l1 therapy, for rcc is allowed with the following exception: i) one prior adjuvant or neoadjuvant therapy for completely resectable rcc is allowed. therapy must have included an agent that targets vascular endothelial growth factor (vegf) pathway or vegf receptors and recurrence must have occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy * life expectancy ≥ 12 weeks * karnofsky performance status (kps) of at least 70% * measurable disease by computed tomography (ct) or magnetic resonance imaging (mri) per recist 1.1 criteria * males and females must agree to follow specific methods of contraception, if applicable exclusion criteria: * active cns brain metastases or leptomeningeal metastases * active, known or suspected autoimmune disease * inadequately treated adrenal insufficiency * history of pulmonary embolism (pe), deep vein thrombosis (dvt), or prior clinically significant venous or non-cva/tia arterial thromboembolic event (eg, internal jugular vein thrombosis) within 3 months prior to treatment assignment (part 1) and randomization (part 2) other protocol-defined inclusion/exclusion criteria apply

Keywords: nktr-214 nivolumab bempeg
evaluation of vler-indiana health information exchange demonstration project

Conditions: Diabetes Mellitus; Asthma; Cardiovascular Diseases; Heart Failure; Osteoporosis

Summary: three out of four veterans receive a portion of their care from non-va providers. on april 9, 2009, president barack obama directed the department of veterans affairs and the department of defense to create the virtual lifetime electronic record (vler). on august 2010, secretary of veterans affairs eric k. shinseki visited indianapolis, and after visiting with leaders from the va health services research \& development (hsr\&d) center of excellence and the regenstrief institute, he made the following public comments regarding the latest partnership between the two institutions: "this new technology allows safer, more secure, and private access to electronic health information which, in turn, enhances our ability to continue providing veterans with the quality care that they have earned." this new technology refers to the vler health program that the indianapolis va is now implementing in partnership with the regenstrief institute and indiana health information exchange (ihie). this va-ihie demonstration project is intended to create the capacity for va institutions to exchange health information with community partners. investigators from the va hsr\&d center on implementing evidence-based practice are active collaborators in building and implementing this program. the va-ihie program provides the bi-directional exchange of health information between va and non-va providers. based on our pilot study of linked va-ihie data, investigators are conducting an evaluation of the impact of the va-ihie demonstration project upon health care quality and cost of veterans by taking advantage of the initiation of the implementation as a natural experiment.

this study will perform a pre-post evaluation of the va-ihie implementation, with a concurrent control group, among veterans seen at the indianapolis va. data on care received by veterans will be obtained for one year before, and one year after, va-ihie enrollment. patients will be recruited into the va-ihie program in a rolling manner over the course of a year, and thus will have different calendar intervals of follow-up. for purposes of evaluation, investigators will approach the va-ihie implementation as a patient-directed intervention given that additional information available from the exchange is available only on a patient-by-patient basis, i.e., a provider cannot use exchange information available for one patient in the care of another. although the va-ihie program will be implemented at the site level, patients will be enrolled individually.

Eligibility criteria:
inclusion criteria: * veteran's receiving care at the indianapolis vamc at least one year prior and one year post va-ihie enrollment * veteran's receiving care from a facility other than the indianapolis vamc one year prior and one year post va-ihie enrollment exclusion criteria: none
impact of biliopancreatic limb lenght on long-term weight loss after roux-en-y gastric bypass

Conditions: Weight Loss

Summary: patients were randomly assigned into 2 groups: those patients undergoing rygb with a bpl of 70cm and those ones undergoing rygb with a bpl of 120 cm. excess bmi loss 5 years after surgery was investigated

patients were randomly assigned into 2 groups: those patients undergoing roux-en-y gastric bypass with a biliopancreatic limb of 70cm and those ones undergoing roux-en-y gastric bypass with a biliopancreatic limb of 120 cm. alimentary limb was constant in both groups (150cm). excess bmi loss 5 years after surgery was investigated

Eligibility criteria:
inclusion criteria: * bmi \>40 kg/m2 * bmi \> 35 kg/m2 with the presence of comorbidities associated to obesity * age older than 18 years exclusion criteria: * patients undergoing other bariatric techniques than rygb * patients undergoing rygb with different bpl or al lengths than that reported for this study * any other surgical procedure added to the bariatric surgery * impossibility to comply with pre-established clinical follow-up.
trial to evaluate efficacy of olanzapine with short-acting 5ht3 inhibitors in chemotherapy-induced nausea & vomiting (cinv) prophylaxis

Conditions: Emesis; Vomiting; Nausea Post Chemotherapy; Nausea; Chemotherapy-induced Nausea and Vomiting

Summary: olanzapine-containing regimens for cinv prophylaxis may provide even better protection than aprepitant-containing regimens.

olanzapine-containing regimens for cinv provide high complete response (cr) rate in patients receiving high emetogenic chemotherapy. olanzapine may be more effective than aprepitant in this setting but cheaper. however, there is no strong evidence supporting the advantages of olanzapine over aprepitant - and this is the reason why aprepitant is still the standard of care. due to high cost aprepitant can be not affordable in low- and middle income countries; this compromises quality of life of cancer patients. on the other hand, recommended olanzapine-based regimen includes palonosetron, whose price is quite high as well and undesired sedation is a common side effect for olanzapine doses that currently recommended, these adverse events precludes wide use of olanzapine in oncology. development of effective, tolerable and affordable regimen for cinv prophylaxis based on low-dose olanzapine and short-acting 5-ht3 inhibitors can improve quality of care for many cancer patients.

Eligibility criteria:
inclusion criteria: 1. high-emetogenic chemotherapy (hec) regimen (e.g., cisplatin ≥70 mg/m2 or doxorubicin ≥60 mg/m2 or carboplatin auc≥4). patients that are prescribed less doses of mentioned agents are still allowed if another high-emetogenic drug will be administered (eg, doxorubicin plus cisplatin); 2. administration of hec component only in first day of the cycle; 3. no previous chemotherapy or radiotherapy; 4. no concomitant quinolone antibiotics administration; 5. ecog ps ≤2; 6. no nausea and vomiting 24 hours before enrollment; 7. adequate hepatic and renal function (eg, alat, asat ≤3 uln, creatinine clearance ≥50 ml/minute). 8. no brain metastases, leptomeningeal carcinomatosis, and chronic diseases such as uncontrolled diabetes mellitus and chronic alcohol consumption. 9. subject willing to participate in the trial and provided informed consent form. exclusion criteria: 1. previous chemotherapy or radiotherapy; 2. moderate- or low- emetogenic chemotherapy; 3. multiday administration of hec agents; 4. ecog ps \>2; 5. history of brain metastases, signs of symptoms of bowel obstruction; 6. nausea and/or vomiting of any genesis 24 hours before enrollment; 7. uncontrolled diabetes mellitus or other metabolic diseases; chronic alcohol consumption. 8. diseases and conditions interfere with subject ability to swallow the drug and to take oral medication; 9. concomitant therapy with olanzapine or other antipsychotic drugs; history of mental illness; 10. concomitant therapy with quinolone antibiotics; 11. contraindications for olanzapine or aprepitant administration; 12. intraperitoneal or intrapleural administration of hec drugs; 13. inadequate hepatic and/or renal function.

Keywords: olanzapine aprepitant cinv nausea vomiting nausea and vomiting antiemetics
18f-fdg pet/ct guided reduced-dose radiotherapy for nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: the purpose of this study is to explore whether 18f-fdg pet/ct guided reduced-dose radiotherapy would maintain survival outcomes in nasopharyngeal carcinoma (npc) patients.

enrolled patients with complete metabolic response (cmr) and more than 70% partial metabolic response (pmr) according to percist criteria at the 25th fraction will receive intensity modulated radiation therapy (imrt) of reduced-dose (prescribed dose, 63.6 gy, 2.12 gy per fractions, 30 fractions), for those who with ≤70% pmr will receive conventional dose (prescribed dose, 70gy, 2.12 gy per fractions, 33 fractions).

Eligibility criteria:
inclusion criteria: 1. pathology confirmed nasopharyngeal squamous cell carcinoma. 2. stage i-iva（8thajcc/uicc staging system). 3. aged 18-80 years. 4. kps≥70. 5. have measurable lesions on 18f-fdg pet/ct before treatment. 6. hgb≥90 g/l，anc≥1.5×109 /l，plt≥80×109 /l. 7. alt,ast\<2.5 fold of uln；tbil\<2.0×uln. 8. ccr≥60ml/min or cr\<1.5×uln. 9. signed informed consent. 10. have follow up condition. exclusion criteria: 1. past malignancies history (except for stage i non-melanoma skin cancer or cervical carcinoma in situ). 2. age \ 80years. 3. pregnancy or lactation. 4. history of previous radiotherapy (except for non-melanomatous skin cancers outside intended rt treatment volume). 5. prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes. 6. with sever infection and internal disease. 7. major organ dysfunction, such as decompensated cardiopulmonary, kidney, liver failure, cannot tolerate surgical treatment.
sleep apnea syndrome in obese women during pregnancy

Conditions: Apnea, Obstructive Sleep; Pregnancy Complications; Pre-Eclampsia; Obesity

Summary: excess weight or obesity is associated with an increased risk of health disorders: high blood pressure, diabetes, cardiovascular risks, dyslipidemia and sleep apneas. during pregnancy in obese women, the risk of preeclampsia increases by three and the risk of fetal death in utero by five. snoring and obstructive sleep apnea (osa) may be associated with increased risk of adverse pregnancy outcomes, including maternal cardio pulmonary status, fetal heart rate and fetal acidosis-basis status by recurrent upper-airway obstruction, hypoventilation, and intermittent nocturnal hypoxia. reports in pregnancy have identified in association with osa and preeclampsia, intrauterine growth restriction and stillbirth. the prevalence of osa among women is estimated to be 2-5%, but it remains underdiagnosed during pregnancy. in sleep apnea syndrome, a few data have shown better pregnancy and fetal outcome with the use continuous positive airway pressure (cpap) therapy. the hypothesis is in obese pregnant women that there could be a significant association between sleep apnea syndrome and hypertensive disorders, preeclampsia and adverse fetal outcomes this is a prospective study of women with a body mass index of 35 kg.m2 or greater. the aim of this study is to determinate the prevalence of sleep apnea syndrome in obese pregnant women and the benefit of cpap on the maternal and fetal outcome.


Eligibility criteria:
inclusion criteria: * age \>18 years * bmi \> 35 * \> 24th weeks of pregnancy * informed consent, * health assurance exclusion criteria: * no informed consent * twin pregnancy or more * no health assurance

Keywords: sleep apnea syndrome obesity pregnancy preeclampsia
a study of khk4827 (brodalumab) in subjects with moderate to severe psoriasis in korea

Conditions: Moderate to Severe Plaque Psoriasis

Summary: the primary objective of this study is to evaluate the efficacy and safety of khk4827 in subjects with moderate to severe plaque psoriasis randomized in a double-blind manner to receive khk4827 or placebo for 12 weeks


Eligibility criteria:
inclusion criteria: * subject has had stable moderate to severe plaque psoriasis for at least 6 months * subject has involved bsa ≧ 10%, pasi ≧ 12, and spga ≧ 3 at screening and at baseline exclusion criteria: * subject diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, or a medication-induced psoriasis, or other skin conditions (e.g., eczema) at screening that would interfere with study evaluations * subject scheduled to undergo a surgical intervention during the study period * subject has any active infection or history of infections as defined in the study protocol * subject has known history of crohn's disease * subject has any other significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol * subject has not stopped using certain psoriasis therapies as defined in the study protocol * subject has previously used any anti-il-17 biologic therapy * subject is pregnant or breast feeding, or planning to become pregnant while enrolled in the study * women of child-bearing potential or fertile men who do not agree to use effective contraception from the day of providing consent through 12 weeks after the last dose of investigational product. * subject has known history or evidence of suicidal ideation (severity of 4 or 5) or any suicidal behavior based on an assessment with the columbia-suicide severity rating scale (c-ssrs) at screening or at baseline * subject has severe depression based on a total score of ≥ 15 on the patient health questionnaire-8 (phq-8) at screening or at baseline * subject has known history or evidence of a psychiatric disorder that, in the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion * subject has known history of alcohol and/or substance abuse within the last 12 months"

Keywords: khk4827 (brodalumab)
resistance exercise in severe knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: this study aim to evaluate pain after different resistance training protocols (placebo, 4 sets of 10rm, 8 sets of 10 rm and 12 sets of 10rm) in patients with severe knee osteoarthritis.


Eligibility criteria:
inclusion criteria: * men and women at least 55 years old * diagnosed with severe knee oa * scheduled for unilateral total knee arthroplasty (tka) surgery exclusion criteria: * pain in the contralateral (non-studied) limb (maximum ≥80 of 100 mm on a visual analog scale (vas) during daily activities) * another hip or knee joint replacement in the previous year * any medical condition in which exercise was contraindicated * participated in exercise programs (\>2 days/week, training at intensities of 10-15rm) in the 6 months prior to the study * history of stroke, brain surgery, major depression, or any self-perceived cognitive alterations that could affect the performance of study tasks

Keywords: resistance training knee osteoarthritis pain
cardiac simulator for surgical planning

Conditions: Congenital Heart Disease in Children

Summary: the goal of this clinical trial is to learn if a computer software program (cardiac simulator) for surgical planning will lead to improvements in patient care by decreasing the incidence of unsuccessful interventions and reinterventions for pediatric patients with congenital heart disease. it is not a commercially available device to treat congenital heart disease in pediatric patients. the main aims are: to provide safe pre-operative testing of surgical approaches with a computer model cardiac simulator. to aid surgeons in envisioning different surgical approaches for each individual patient. to bolster the standard of care surgical planning discussions which will be particularly useful for patients with unique, complex congenital heart disease. participants will: consent to being randomized with a 50% chance of receiving standard of care "on the fly" surgical planning discussion as is current practice or assisted surgical planning discussion with the aid of the computer software cardiac simulator. receive results of their computer simulated findings during their surgical planning discussion if they are in the cardiac simulator group.

the computer software will be developed at the cardiovascular biomechanics computation lab at stanford.

Eligibility criteria:
inclusion criteria: * the inclusion criteria are pediatric patients ages 0-17 with a congenital heart disease (chd) diagnosis of 1) congenitally corrected transposition of the great arteries (cc-tga) with ventricular septal defect (vsd), 2) double outlet right ventricle (dorv) with remote vsd, or 3) other single ventricle conditions. exclusion criteria: * adult patients with chd.